Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GRIP Molecular Technologies has developed a patented graphene-based electronic biosensor platform enabling rapid, lab-quality diagnostic testing at home or point-of-care. The technology allows detection of multiple pathogens and immune responses from self-collected samples with results displayed on smartphones. Clinical feasibility studies have been successful; the company aims to commercialize its first products targeting upper respiratory infections such as COVID‑19 and flu. Regulatory submissions are being prepared.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Bruce Batten Communications.